Renal Cell Carcinoma | Topics

Hand-Foot Skin Reaction Secondary to Sunitinib in a Patient With Metastatic Clear Cell Renal Cell Carcinoma
May 15, 2021

Another installment of Clinical Quandaries is presented by Karen Férez-Blando, MD, and colleagues of a 45-year-old man with a diagnosis of intermediate-risk stage IV clear cell renal carcinoma who develops grade 2 hand-foot skin reaction on sunitinib therapy.

Pembrolizumab Plus Lenvatinib Earns Priority Review in 2 Disease Indications
May 06, 2021

In the advanced treatment setting, an FDA decision has indicated that the combination of pembrolizumab and lenvatinib may soon be available for certain patients with endometrial tumors and renal cell carcinoma.

New Potential Frontline Standards for RCC Are Spotlighted at Genitourinary Cancers Symposium
April 25, 2021

ONCOLOGY reviews key updates in the treatment of renal cell carcinoma to come out of the Genitourinary Cancers Symposium.